Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial to Evaluate the Effects of Atomoxetine on Impulsivity in Behavioral Laboratory Tasks in Adult ADHD Patients

NCT05278104 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05278104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05278104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial to Evaluate the Effects of Atomoxetine on Impulsivity in Behavioral Laboratory Tasks in Adult ADHD Patients
Lead sponsor
Boehringer Ingelheim
Phase
Not applicable
Overall status
Completed
Start date
September 14, 2023
Completion date
October 30, 2024
Enrollment
63 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder